WebDoctor Encyclopedia

Endocrine

Oncocytic (Hürthle cell) thyroid carcinoma

Oncocytic thyroid carcinoma, formerly called Hürthle cell carcinoma, is an uncommon thyroid cancer made of large mitochondria-rich cells. It usually appears as a neck lump in older adults and is treated mainly with surgery.

Medically reviewed Last reviewed October 17, 2026

What is oncocytic thyroid carcinoma?

Oncocytic thyroid carcinoma is a rare type of thyroid cancer made up mainly of oncocytic cells. These are large thyroid cells packed with mitochondria, the energy-producing parts of the cell, which give them a pink, granular look under the microscope.

For many years it was called Hürthle cell carcinoma, and it was regarded as a variant of follicular thyroid cancer. Gene studies have shown that it is a separate disease, and the 2022 WHO classification now calls it oncocytic carcinoma of the thyroid (Baloch et al., 2022).

It makes up about 3-5% of thyroid cancers. It usually affects people in their 50s and 60s and is more common in women (Goffredo, Roman and Sosa, 2013).

Most oncocytic carcinomas are found at an early stage and are cured by surgery. Compared with other well-differentiated thyroid cancers, though, it is more likely to spread and less likely to take up radioactive iodine, which affects how it is treated and monitored (Kure and Ohashi, 2020).

1. Key facts at a glance

Feature Details
Type of cancer Differentiated thyroid cancer made of oncocytic (Hürthle) cells
How common About 3-5% of thyroid cancers
Typical age Average about 55-60 years; older than for papillary cancer
Sex About two to three times more common in women
Key symptoms Painless lump in the neck; often no symptoms
Typical spread Lymph nodes, lungs and bone
Main treatment Surgery (lobectomy or total thyroidectomy); radioactive iodine for some
Special feature Often takes up radioactive iodine poorly
Outlook Excellent when minimally invasive; poorer when widely invasive or spread

2. Causes and risk factors

The exact cause is not known. Oncocytic carcinoma has a distinctive genetic make-up.

Feature Explanation
Mitochondrial DNA changes Mutations in genes for mitochondrial complex I are common (Gopal et al., 2018)
Chromosome losses Many tumours lose whole copies of chromosomes, leaving a near-haploid genome
TERT promoter mutations Found especially in more aggressive tumours
Few BRAF changes Unlike papillary thyroid cancer

Possible risk factors

Risk factor Notes
Age over 50 Risk rises with age
Female sex More common in women
Radiation to the neck in childhood A risk for thyroid cancers in general
Thyroid nodules or goitre Most nodules are benign, but any growing nodule should be assessed
Family history Rare familial cases occur

Benign oncocytic adenomas are much more common than oncocytic carcinoma. The two look similar, and the difference is only seen when the whole nodule is examined after surgery.

3. How does it look

In the neck

Feature Description
Lump A firm, usually painless swelling in the front of the neck that moves when swallowing
Size Often larger than other thyroid nodules, frequently 3-4 cm or more
Lymph nodes Sometimes enlarged nodes at the side of the neck
Skin Normal over the lump in most people

On ultrasound

Oncocytic carcinoma often appears as a solid nodule that may be well defined with a thin dark rim. It can look similar to a benign nodule, so the scan alone cannot confirm cancer.

Under the microscope

Feature Description
Cells Large cells with abundant pink, granular cytoplasm (over 75% of the tumour)
Nuclei Round, often with a prominent nucleolus; no papillary-type nuclear features
Capsule Usually surrounded by a fibrous capsule
Invasion Cancer is diagnosed when cells break through the capsule or invade blood vessels
High-grade features Necrosis or many dividing cells suggest more aggressive disease

Subtypes by invasion

Subtype Description Behaviour
Minimally invasive Only capsular invasion Very low risk
Encapsulated angioinvasive Invasion into blood vessels Risk rises with the number of vessels involved (4 or more is higher risk)
Widely invasive Extensive invasion into the thyroid and beyond Higher risk of spread

4. Symptoms

Common symptoms

Many people have no symptoms. The tumour is often found as a lump or on a scan done for another reason.

  • A lump or swelling in the front of the neck
  • Swollen lymph nodes in the neck
  • A feeling of pressure or fullness in the neck
  • Difficulty swallowing if the lump is large
  • Hoarse voice that does not improve, if a nerve to the voice box is affected
  • Breathing difficulty if the lump presses on the windpipe (rare)

Symptoms of spread

Site Possible symptoms
Lungs Cough, breathlessness or coughing up blood (often no symptoms)
Bone Bone pain, fractures or, in the spine, back pain and weakness
Brain Headache, seizures (rare)

Thyroid hormone levels are usually normal, so people do not normally feel tired or notice weight changes from the cancer itself.

When to seek medical advice

See a doctor if you notice a new neck lump, a lump that is growing, or hoarseness lasting more than 3 weeks.

Seek urgent help for difficulty breathing or swallowing.

5. Diagnosis

Test Purpose
Thyroid ultrasound Shows the nodule and checks neck lymph nodes
Thyroid blood tests TSH and thyroid hormones, usually normal
Fine-needle aspiration (FNA) Sample of cells from the nodule
Molecular tests on FNA Help estimate cancer risk in uncertain nodules
Diagnostic surgery (lobectomy) Often needed to confirm or rule out cancer
CT or PET-CT For large or widely invasive tumours, or suspected spread
Thyroglobulin blood test A tumour marker used after surgery

Why FNA often cannot confirm cancer

An FNA of an oncocytic nodule is often reported as “follicular neoplasm, oncocytic type” (Bethesda category IV). This means the cells could come from either a benign adenoma or a carcinoma (Ali et al., 2023).

The difference depends on capsular or vascular invasion, which can only be seen when the whole nodule is removed and examined. For this reason, many people have a diagnostic lobectomy (removal of half the thyroid).

Staging

Oncocytic carcinoma is staged with the AJCC TNM system for differentiated thyroid cancer. Age at diagnosis is part of the staging: people under 55 are usually stage I or II even if the cancer has spread to lymph nodes.

Conditions that can look similar

Condition How it differs
Oncocytic adenoma Benign; no capsular or vascular invasion
Follicular thyroid carcinoma Fewer oncocytic cells; different gene changes
Oncocytic papillary thyroid carcinoma Has papillary-type nuclear features
Medullary thyroid carcinoma Raised calcitonin; different stains
Oncocytic change in thyroiditis Inflammation without a single tumour

6. Treatment

Treatment is guided by the size, invasion, spread and risk of the cancer, following guidelines such as those of the American Thyroid Association and ESMO (Haugen et al., 2016; Filetti et al., 2019).

Surgery

Situation Usual surgery
Small, minimally invasive tumour Lobectomy alone may be enough
Larger or angioinvasive tumour Total thyroidectomy (completion surgery if lobectomy was done first)
Lymph node spread Neck dissection to remove affected nodes
Widely invasive tumour Total thyroidectomy with removal of any invaded structures

Radioactive iodine (RAI)

RAI is used to destroy remaining thyroid tissue and microscopic cancer after total thyroidectomy. Oncocytic carcinoma often takes up iodine poorly, so RAI is used selectively, mainly for higher-risk tumours and for disease that can be shown to absorb iodine (Bischoff et al., 2024).

What radioactive iodine treatment involves

Step What to expect
Preparation A low-iodine diet for about 1-2 weeks, plus either injections of recombinant TSH or a short break from levothyroxine
Taking the dose A capsule or drink of radioactive iodine, usually given in hospital
Isolation Often 1-3 days in a shielded room, depending on the dose and local rules
At home Limited close contact with children and pregnant women for a few days
Post-treatment scan A whole-body scan about a week later shows where the iodine was taken up

If the post-treatment scan shows no uptake in known cancer, further RAI is unlikely to help. The team then relies on surgery, radiotherapy or targeted drugs instead.

Thyroid hormone tablets

After total thyroidectomy, everyone needs levothyroxine for life. In higher-risk cancer, the dose may be set to keep TSH slightly low, which reduces stimulation of any remaining cancer cells.

Treatment of advanced disease

Treatment Notes
Further surgery For neck recurrence
External beam radiotherapy For tumour left in the neck or painful bone deposits
Lenvatinib or sorafenib Targeted tablets for progressive, radioiodine-refractory cancer (Schlumberger et al., 2015)
Cabozantinib After earlier targeted therapy
Bone-strengthening drugs Zoledronic acid or denosumab for bone spread
Clinical trials Including drugs targeting the tumour’s metabolism

Systemic treatment for advanced thyroid cancer is summarised in the ESMO guideline update (Filetti et al., 2022).

Side effects

Treatment Possible side effects
Thyroid surgery Hoarse voice from nerve injury; low calcium from parathyroid gland damage (usually temporary)
Radioactive iodine Dry mouth, altered taste, swelling of salivary glands; short-term radiation precautions
Levothyroxine Few side effects at the correct dose; palpitations or bone thinning if the dose is too high
Lenvatinib and similar drugs High blood pressure, diarrhoea, tiredness, weight loss, hand-foot skin reactions

7. Outlook (prognosis)

Group Approximate outlook
Minimally invasive Excellent; recurrence is rare
Encapsulated angioinvasive, few vessels Very good
Widely invasive Higher risk of recurrence and spread
Distant spread Poorer; often radioiodine-refractory
Overall (US national data) Most people survive long term, although survival is somewhat lower than for follicular cancer (Goffredo, Roman and Sosa, 2013)

Older age, larger tumour, extensive vascular invasion and distant spread are linked to a less favourable outlook.

Even when oncocytic carcinoma has spread, it often grows slowly, and many people live for years with stable disease. Targeted drugs are usually started only when the cancer is growing or causing symptoms, not simply because small deposits are present.

8. Follow-up

Follow-up Purpose
Thyroglobulin and thyroglobulin antibodies Rising levels can signal recurrence
Neck ultrasound Checks for recurrence in the neck
TSH and thyroid hormone levels Adjust levothyroxine dose
CT or PET-CT When thyroglobulin rises but iodine scans are negative
Calcium checks After total thyroidectomy

Follow-up is usually lifelong, but becomes less frequent over time if there is no sign of the cancer.

9. Living with oncocytic thyroid carcinoma

  • Take levothyroxine every day, ideally on an empty stomach at the same time
  • Keep blood test appointments to check your hormone dose and thyroglobulin
  • Ask about voice therapy if your voice changes after surgery
  • Follow radiation safety advice for a few days after RAI
  • Join a thyroid cancer support group for practical and emotional support
  • Report new neck lumps, bone pain or a persistent cough

10. Frequently asked questions

Question Answer
Is Hürthle cell cancer the same as oncocytic carcinoma? Yes. Oncocytic carcinoma is the current WHO name
Why did I need surgery to get a diagnosis? Cancer is confirmed only by seeing invasion in the removed nodule
Will I need radioactive iodine? Not always; it depends on your risk and whether the tumour absorbs iodine
Can I live normally without a thyroid? Yes, with daily levothyroxine tablets
Is it inherited? Usually not
Why is my thyroglobulin checked? Only thyroid cells make it, so after total thyroidectomy a rising level may mean the cancer is back
Can I have children after treatment? Yes. Pregnancy is usually advised to wait 6-12 months after radioactive iodine

11. Questions to ask your care team

  • Is my cancer minimally invasive, angioinvasive or widely invasive?
  • Do I need total thyroidectomy or is lobectomy enough?
  • Will radioactive iodine help in my case?
  • What TSH level should we aim for?
  • How often will I need blood tests and scans?
  • What options are there if the cancer comes back?

Resources

  1. Ali, S.Z. et al. (2023) ‘The 2023 Bethesda System for reporting thyroid cytopathology’, Journal of the American Society of Cytopathology, 12(5), pp. 319-325.
  2. Baloch, Z.W. et al. (2022) ‘Overview of the 2022 WHO classification of thyroid neoplasms’, Endocrine Pathology, 33(1), pp. 27-63.
  3. Bischoff, L.A. et al. (2024) ‘Molecular alterations and comprehensive clinical management of oncocytic thyroid carcinoma: a review and multidisciplinary 2023 update’, JAMA Otolaryngology – Head and Neck Surgery, 150(3), pp. 265-272.
  4. Filetti, S. et al. (2019) ‘Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 30(12), pp. 1856-1883.
  5. Filetti, S. et al. (2022) ‘ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer’, Annals of Oncology, 33(7), pp. 674-684.
  6. Goffredo, P., Roman, S.A. and Sosa, J.A. (2013) ‘Hurthle cell carcinoma: a population-level analysis of 3311 patients’, Cancer, 119(3), pp. 504-511.
  7. Gopal, R.K. et al. (2018) ‘Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma’, Cancer Cell, 34(2), pp. 242-255.
  8. Haugen, B.R. et al. (2016) ‘2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer’, Thyroid, 26(1), pp. 1-133.
  9. Kure, S. and Ohashi, R. (2020) ‘Thyroid Hürthle cell carcinoma: clinical, pathological, and molecular features’, Cancers, 13(1), 26.
  10. Schlumberger, M. et al. (2015) ‘Lenvatinib versus placebo in radioiodine-refractory thyroid cancer’, New England Journal of Medicine, 372(7), pp. 621-630.
  11. National Cancer Institute (2026) Thyroid Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.